Log in

NASDAQ:CTMXCytomX Therapeutics Stock Price, Forecast & News

$8.05
-0.07 (-0.86 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.93
Now: $8.05
$8.27
50-Day Range
$8.05
MA: $10.09
$14.64
52-Week Range
$3.60
Now: $8.05
$15.44
Volume602,900 shs
Average Volume900,172 shs
Market Capitalization$369.66 million
P/E RatioN/A
Dividend YieldN/A
Beta0.7
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Read More
CytomX Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$57.49 million
Book Value$1.12 per share

Profitability

Net Income$-102,240,000.00

Miscellaneous

Employees137
Market Cap$369.66 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

How has CytomX Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTMX stock has increased by 37.1% and is now trading at $8.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CytomX Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytomX Therapeutics.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for CytomX Therapeutics.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported $0.26 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.60. The biotechnology company had revenue of $49.59 million for the quarter, compared to analysts' expectations of $26.93 million. CytomX Therapeutics had a negative return on equity of 99.72% and a negative net margin of 97.83%. View CytomX Therapeutics' earnings history.

What price target have analysts set for CTMX?

9 equities research analysts have issued twelve-month price targets for CytomX Therapeutics' shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate CytomX Therapeutics' share price to reach $12.38 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price. View analysts' price targets for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (4/3/2020)
  • 2. Nomura Securities analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019)

Has CytomX Therapeutics been receiving favorable news coverage?

Media stories about CTMX stock have been trending extremely negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutCytomX Therapeutics.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,070,000 shares, a decrease of 14.4% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 536,100 shares, the short-interest ratio is presently 2.0 days. Approximately 2.4% of the shares of the stock are short sold. View CytomX Therapeutics' Current Options Chain.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
  • Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
  • Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
  • Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
  • Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.65%), Victory Capital Management Inc. (6.04%), Victory Capital Management Inc. (6.04%), State Street Corp (2.15%), First Manhattan Co. (1.73%) and Nuveen Asset Management LLC (1.57%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Lloyd A Rowland and Sean A Mccarthy. View institutional ownership trends for CytomX Therapeutics.

Which major investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., First Manhattan Co., Squarepoint Ops LLC, Two Sigma Investments LP, Deutsche Bank AG, BlackRock Inc., GSA Capital Partners LLP, and Victory Capital Management Inc.. View insider buying and selling activity for CytomX Therapeutics.

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Granahan Investment Management Inc. MA, Connor Clark & Lunn Investment Management Ltd., Acadian Asset Management LLC, Russell Investments Group Ltd., Sumitomo Mitsui Trust Holdings Inc., Thrivent Financial for Lutherans, and Geode Capital Management LLC. View insider buying and selling activity for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $8.05.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $369.66 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.